NEW YORK – Liquid biopsy developer Angle said on Monday that it has submitted a full de novo submission to the US Food and Drug Administration for its Parsortix system for use with metastatic breast cancer (MBC) patients.
The UK-based firm said the submission provides a data package that highlights Parsortix's ability to harvest circulating tumor cells (CTCs) from MBC patient blood samples for downstream analysis.